Literature DB >> 7986409

Reversible renal failure caused by a microsporidian infection.

E J Aarons1, D Woodrow, W S Hollister, E U Canning, N Francis, B G Gazzard.   

Abstract

OBJECTIVE: To report a case of renal failure associated with microsporidian infection in an HIV-seropositive patient.
DESIGN: Case report.
SETTING: Chelsea and Westminster Hospital, London, England, UK. PATIENT: An HIV-seropositive patient presented febrile with abdominal pain who developed renal failure. Renal biopsy and urinalysis showed infection with a microsporidian of the genus Encephalitozoon. INTERVENTION: Treatment with albendazole (400 mg) twice daily was associated with disappearance of infection from the urine, clinical improvement and return of renal function virtually to normal.
CONCLUSION: HIV-seropositive individuals with renal failure should have urine screened for microsporidia. The administration of albendazole in such cases may reverse renal failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986409     DOI: 10.1097/00002030-199408000-00013

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro.

Authors:  E S Didier
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 2.  Molecular techniques for detection, species differentiation, and phylogenetic analysis of microsporidia.

Authors:  C Franzen; A Müller
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 3.  Zoonotic potential of the microsporidia.

Authors:  Alexander Mathis; Rainer Weber; Peter Deplazes
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

4.  In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives.

Authors:  S K Katiyar; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.